JPWO2006001471A1 - グルコース応答性インスリン分泌を促進するための医薬組成物 - Google Patents

グルコース応答性インスリン分泌を促進するための医薬組成物 Download PDF

Info

Publication number
JPWO2006001471A1
JPWO2006001471A1 JP2006528728A JP2006528728A JPWO2006001471A1 JP WO2006001471 A1 JPWO2006001471 A1 JP WO2006001471A1 JP 2006528728 A JP2006528728 A JP 2006528728A JP 2006528728 A JP2006528728 A JP 2006528728A JP WO2006001471 A1 JPWO2006001471 A1 JP WO2006001471A1
Authority
JP
Japan
Prior art keywords
group
lower alkyl
alkyl group
hydrogen atom
substituent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2006528728A
Other languages
English (en)
Japanese (ja)
Inventor
寿郎 酒井
寿郎 酒井
児玉　龍彦
龍彦 児玉
健太 馬郡
健太 馬郡
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Tokyo NUC
Original Assignee
University of Tokyo NUC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Tokyo NUC filed Critical University of Tokyo NUC
Publication of JPWO2006001471A1 publication Critical patent/JPWO2006001471A1/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4355—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2006528728A 2004-06-29 2005-06-29 グルコース応答性インスリン分泌を促進するための医薬組成物 Pending JPWO2006001471A1 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2004192118 2004-06-29
JP2004192118 2004-06-29
PCT/JP2005/011898 WO2006001471A1 (fr) 2004-06-29 2005-06-29 Composition medicale favorisant la secretion d'insuline en reponse au glucose

Publications (1)

Publication Number Publication Date
JPWO2006001471A1 true JPWO2006001471A1 (ja) 2008-04-17

Family

ID=35781892

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006528728A Pending JPWO2006001471A1 (ja) 2004-06-29 2005-06-29 グルコース応答性インスリン分泌を促進するための医薬組成物

Country Status (2)

Country Link
JP (1) JPWO2006001471A1 (fr)
WO (1) WO2006001471A1 (fr)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003029445A1 (fr) * 2001-09-27 2003-04-10 Cardion Ag Procede de production de cellules presentant un etat de type cellule beta secretrice d'insuline
WO2003050249A2 (fr) * 2001-12-07 2003-06-19 Geron Corporation Cellules d'ilots pancreatiques provenant de cellules souches embryonnaires humaines

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030082155A1 (en) * 1999-12-06 2003-05-01 Habener Joel F. Stem cells of the islets of langerhans and their use in treating diabetes mellitus
US20010046489A1 (en) * 1999-12-06 2001-11-29 Habener Joel E. Stem cells of the islets of langerhans and their use in treating diabetes mellitus
AU2429201A (en) * 1999-12-10 2001-06-18 General Hospital Corporation, The Methods to stimulate insulin production by pancreatic beta-cells
CN1668324A (zh) * 2002-05-28 2005-09-14 诺沃塞尔公司 用于胰岛素产生细胞的方法、组合物及生长与分化因子
CA2494040A1 (fr) * 2002-07-29 2004-02-05 Es Cell International Pte Ltd. Procede en plusieurs etapes de differenciation des cellules sensibles a l'insuline positive, au glucose

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003029445A1 (fr) * 2001-09-27 2003-04-10 Cardion Ag Procede de production de cellules presentant un etat de type cellule beta secretrice d'insuline
WO2003050249A2 (fr) * 2001-12-07 2003-06-19 Geron Corporation Cellules d'ilots pancreatiques provenant de cellules souches embryonnaires humaines

Also Published As

Publication number Publication date
WO2006001471A1 (fr) 2006-01-05

Similar Documents

Publication Publication Date Title
EP3596053B1 (fr) Agonistes du récepteur farnésoïde x et leurs utilisations
JP6387010B2 (ja) 血中グルコースレベルを制御することによる糖尿病及び関連容態の処置のための組成物、方法及び使用
CA2825456C (fr) Traitement de la lipodystrophie
EP2380566A2 (fr) Traitement de la résistance d'insuline ou maladies associées à la résistance d'insuline utilisant Stéviol ou Isosteviol
EP3210969B1 (fr) Activateur des canaux kcnq2-5
EA023277B1 (ru) Терапия неврологических заболеваний на основе баклофена и акампросата
JP2000256299A (ja) 甲状腺レセプターリガンドとしてのシアノ基含有オキサミド酸及び誘導体
KR20170082494A (ko) 결정 형태의 글루타미나아제 억제제
TW200808792A (en) 3-aminoimidazo[1,2-a]pyridine derivatives
TW201619142A (zh) 利用替唑尼特（ｔｉｚｏｘａｎｉｄｅ）、其類似物或鹽類之前驅藥的組成物及治療方法
EP1202729A1 (fr) Inhibiteurs de transport de phosphate
US11844779B2 (en) PKC-Delta-I inhibitor formulations and uses thereof
US6803480B2 (en) Diphenylmethane derivatives
TW200911763A (en) Substituted amino-quinazolinones, medicaments comprising said compound, their use and their method of manufacture
RU2648242C2 (ru) Производное имидазопиридина, используемое для лечения сахарного диабета
JP6931042B2 (ja) 甲状腺ベータアゴニストの使用
TWI220650B (en) Treatment of sexual dysfunction
JPWO2006001471A1 (ja) グルコース応答性インスリン分泌を促進するための医薬組成物
US20030216449A1 (en) Phosphate transport inhibitors
CN105732465B (zh) 苯基吲哚类化合物及其制备方法和应用
EP2307013B1 (fr) Compositions de donneurs d oxyde nitrique contenant du furoxane soulageant la douleur et leurs utilisations
JPH093037A (ja) フェニルスルホン誘導体及びその製造方法
CN107304180B (zh) 苯甲酰胺类衍生物、其制备方法及其在医药上的用途
JP2023502893A (ja) プロスタグランジンアナログおよびその用途
AU2015268725A1 (en) Treatment for lipodystrophy

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20080602

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110706

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20120123